Dehao Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dehao Zhu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Hui Shi
Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
2 shared publications - Huihui Chi
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China
2 shared publications - Jialin Teng
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Jinchao Jia
Department of Rheumatology and Immunology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine No. 197 Ruijin Second Road Shanghai 200025 China
2 shared publications - Qiongyi Hu
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai
2 shared publications - Tingting Liu
Department of Rheumatology and Immunology Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China
2 shared publications
Latest Publications
- Open Access
- 1 September 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001665
Glycosylation of anti-dsDNA IgG correlates with organ involvement in treatment-naïve patients with systemic lupus erythematosus
Objective: This study aimed to leverage machine learning algorithms to explore the relationship between anti-double-stranded DNA (anti-dsDNA) immunoglobulin G (IgG) glycosylation and the degree of organ involvement in patients with SLE. Methods and analysis: We enrolled 86 consecutive treatment-naïve patients with SLE positive for anti-dsDNA antibodies from the Department of Rheumatology and Immunology at Ruijin Hospital, Shanghai, between 2017 and 2019. We quantified and classified the degree of organ involvement in patients with SLE and analysed each glycoform and a combination of glycoforms of purified anti-dsDNA IgG. A random forest classifier and artificial neural network were applied to evaluate the correlation between the levels of glycoform pairs and the degree of organ involvement. Results: Pearson’s correlation analysis revealed a strong connection between the involved and uninvolved organs in patients with SLE. Random forest analysis showed that the combination of IgG1Gal and IgG3/4Bis had the highest accuracy (0.7692) and area under the curve (0.8187). In terms of predicting the degree of involvement using an artificial neural network, IgG3/4Bis and IgG1Gal showed the lowest mean squared error (0.0244). Conclusions: Our study showed the effectiveness of combining glycoforms to classify and predict the degree of SLE organ involvement. Different glycoforms were correlated with the involvement degree to various extents, and the combination of anti-dsDNA IgG3/4Bis and IgG1Gal exhibited the best correlation with organ involvement.
- 1 September 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001665
Open AccessGlycosylation of anti-dsDNA IgG correlates with organ involvement in treatment-naïve patients with systemic lupus erythematosus
Objective: This study aimed to leverage machine learning algorithms to explore the relationship between anti-double-stranded DNA (anti-dsDNA) immunoglobulin G (IgG) glycosylation and the degree of organ involvement in patients with SLE. Methods and analysis: We enrolled 86 consecutive treatment-naïve patients with SLE positive for anti-dsDNA antibodies from the Department of Rheumatology and Immunology at Ruijin Hospital, Shanghai, between 2017 and 2019. We quantified and classified the degree of organ involvement in patients with SLE and analysed each glycoform and a combination of glycoforms of purified anti-dsDNA IgG. A random forest classifier and artificial neural network were applied to evaluate the correlation between the levels of glycoform pairs and the degree of organ involvement. Results: Pearson’s correlation analysis revealed a strong connection between the involved and uninvolved organs in patients with SLE. Random forest analysis showed that the combination of IgG1Gal and IgG3/4Bis had the highest accuracy (0.7692) and area under the curve (0.8187). In terms of predicting the degree of involvement using an artificial neural network, IgG3/4Bis and IgG1Gal showed the lowest mean squared error (0.0244). Conclusions: Our study showed the effectiveness of combining glycoforms to classify and predict the degree of SLE organ involvement. Different glycoforms were correlated with the involvement degree to various extents, and the combination of anti-dsDNA IgG3/4Bis and IgG1Gal exhibited the best correlation with organ involvement.
- Top Cited PapersOpen Access
- 31 July 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (5) , 612-627
Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome
Macrophage activation syndrome (MAS) is believed to be caused by inappropriate proliferation and activation of the mononuclear phagocytic system. Adult-onset Still disease (AOSD) is characterized by neutrophil activation and a cytokine storm, which can lead to the severe and potentially life-threatening complication of MAS. RNA sequencing revealed that neutrophils may play a distinct role and enhance the innate immunity of patients with AOSD with MAS (AOSD-MAS). In the CpG-induced secondary hemophagocytic lymphohistiocytosis (HLH) model, the depletion of neutrophils significantly reduced cytokine levels with effects comparable with monocyte depletion. Significant enrichment was observed in the type I/II interferon and JAK-STAT pathways in neutrophils from patients with AOSD-MAS. Treatment of 10 patients with refractory AOSD-MAS with ruxolitinib led to the resolution of inflammatory parameters and clinical symptoms. RNA sequencing and ex vivo assays confirmed that ruxolitinib suppressed aberrant NETosis and STAT3/STAT5 signaling. In vivo, PAD4 knockout further confirmed the pathogenic role of NETosis in a secondary HLH model. Moreover, the selective inhibition of STAT3 or STAT5 alleviated systemic inflammation. Ten functional variants were identified in genes related to the JAK-STAT pathway, however, their clinical relevance requires further validation. These findings suggest that ruxolitinib has the potential to facilitate disease remission in patients with refractory AOSD-MAS by broadly inhibiting JAK-STAT signaling and modulating neutrophil activation and NETosis.
- 31 July 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (5) , 612-627
Top Cited PapersOpen AccessRuxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome
Macrophage activation syndrome (MAS) is believed to be caused by inappropriate proliferation and activation of the mononuclear phagocytic system. Adult-onset Still disease (AOSD) is characterized by neutrophil activation and a cytokine storm, which can lead to the severe and potentially life-threatening complication of MAS. RNA sequencing revealed that neutrophils may play a distinct role and enhance the innate immunity of patients with AOSD with MAS (AOSD-MAS). In the CpG-induced secondary hemophagocytic lymphohistiocytosis (HLH) model, the depletion of neutrophils significantly reduced cytokine levels with effects comparable with monocyte depletion. Significant enrichment was observed in the type I/II interferon and JAK-STAT pathways in neutrophils from patients with AOSD-MAS. Treatment of 10 patients with refractory AOSD-MAS with ruxolitinib led to the resolution of inflammatory parameters and clinical symptoms. RNA sequencing and ex vivo assays confirmed that ruxolitinib suppressed aberrant NETosis and STAT3/STAT5 signaling. In vivo, PAD4 knockout further confirmed the pathogenic role of NETosis in a secondary HLH model. Moreover, the selective inhibition of STAT3 or STAT5 alleviated systemic inflammation. Ten functional variants were identified in genes related to the JAK-STAT pathway, however, their clinical relevance requires further validation. These findings suggest that ruxolitinib has the potential to facilitate disease remission in patients with refractory AOSD-MAS by broadly inhibiting JAK-STAT signaling and modulating neutrophil activation and NETosis.
- 1 October 2021
- Published by Elsevier in Cellular Immunology
- Vol. 368, 104421
Epigallocatechin-3 gallate regulates macrophage subtypes and immunometabolism to ameliorate experimental autoimmune encephalomyelitis
- 1 October 2021
- Published by Elsevier in Cellular Immunology
- Vol. 368, 104421
Epigallocatechin-3 gallate regulates macrophage subtypes and immunometabolism to ameliorate experimental autoimmune encephalomyelitis